---
title: "Normalized membrane ratio of TROP2 predicts response to datopotamab deruxtecan in NSCLC"
id: "nature-1-normalized-membrane-ratio-of-trop2-as-a-predictor-of-clinical-outcomes-with"
canonical_url: "https://medichelpline.com/clinical-feed/nature-1-normalized-membrane-ratio-of-trop2-as-a-predictor-of-clinical-outcomes-with"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04716-9"
published_at: "2026-11-11T11:19:06.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Normalized membrane ratio of TROP2 predicts response to datopotamab deruxtecan in NSCLC
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-1-normalized-membrane-ratio-of-trop2-as-a-predictor-of-clinical-outcomes-with
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04716-9)
- **Published At:** 2026-11-11T11:19:06.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Investigators developed a computational pathology score—TROP2 quantitative continuous scoring (QCS)—to measure **TROP2** expression at single-cell resolution from IHC slides. - QCS separately quantified membrane and cytoplasmic **TROP2** and produced a normalized membrane ratio (NMR): membrane / (membrane + cytoplasmic) for tumor cells. - The QCS approach was trained and applied in the TROPION-PanTumor01 biomarker-evaluable set (n = 115), where NMR was derived. - The NMR cut-point was optimized and then validated in the primary intended-use population of the TROPION-Lung01 trial (n = 221; biomarker-evaluable population n = 352). - In patients treated with **datopotamab deruxtecan** (Dato-DXd), progression-free survival (PFS) was longer for NMR-positive versus NMR-negative samples (median 7.2 versus 4.0 months; hazard ratio 0.40, 95% CI 0.25–0.64). - No PFS difference by NMR status was observed in docetaxel-treated patients (median 4.1 versus 4.4 months; hazard ratio 0.94, 95% CI 0.59–1.49). - A treatment-by-biomarker interaction was reported (P = 0.0098), which the authors noted indicates that **NMR** may be a predictive biomarker for Dato-DXd. - The study cohort focused on patients with advanced nonsquamous NSCLC without actionable genomic alterations as the primary intended-use population. - The source did not report certain methodological details such as exact algorithm hyperparameters, staining protocols beyond IHC, nor specific clinical dosing regimens within this summary.
## Clinical Analysis & Structured Key Points
Loading [MathJax]/jax/output/HTML-CSS/config.js ## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41591-026-04716-9#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Medicine](https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg) ](https://www.nature.com/nm) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-026-04716-9) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nm/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nm/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nm/news-and-comment) * [ Podcasts ](https://www.nature.com/nm/podcast) * [ Current issue ](https://www.nature.com/nm/current-issue) * [ Collections ](https://www.nature.com/nm/collections) * [Follow us on Facebook ](https://www.facebook.com/Nature-Medicine-193691346949/) * [Follow us on X ](https://twitter.com/naturemedicine) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nm/aims) * [ Journal Information ](https://www.nature.com/nm/journal-information) * [ Editors ](https://www.nature.com/nm/editors) * [ Journal Metrics ](https://www.nature.com/nm/journal-impact) * [ Research Cross-Journal Editorial Team ](https://www.nature.com/nm/research-cross-journal-editorial-team) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nm/reviews-cross-journal-editorial-team) * [ Statistical Advisory Panel ](https://www.nature.com/nm/statistics-advisory-panel) * [ Our publishing models ](https://www.nature.com/nm/our-publishing-models) * [ Editorial Values Statement ](https://www.nature.com/nm/editorial-values-statement) * [ Editorial Policies ](https://www.nature.com/nm/editorial-policies) * [ Content Types ](https://www.nature.com/nm/content) * [ Web Feeds ](https://www.nature.com/nm/web-feeds) * [ Contact ](https://www.nature.com/nm/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ Submission Guidelines ](https://www.nature.com/nm/submission-guidelines) * [ For Reviewers ](https://www.nature.com/nm/for-reviewers) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/nm/open-access-funding) * [Submit manuscript ](https://mts-nmed.nature.com/cgi-bin/main.plex) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) 1. [nature](https://www.nature.com/) 2. [nature medicine](https://www.nature.com/nm) 3. [articles](https://www.nature.com/nm/articles?type=article) 4. article Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer [ Download PDF ](https://www.nature.com/articles/s41591-026-04716-9.pdf) [ Download PDF ](https://www.nature.com/articles/s41591-026-04716-9.pdf) * Article * [Open access](https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research) * Published: 11 November 2026 # Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer * [Marina C. Garassino](https://www.nature.com/articles/s41591-026-04716-9#auth-Marina_C_-Garassino-Aff1)[1](https://www.nature.com/articles/s41591-026-04716-9#Aff1), * [Myung-Ju Ahn](https://www.nature.com/articles/s41591-026-04716-9#auth-Myung_Ju-Ahn-Aff2)[2](https://www.nature.com/articles/s41591-026-04716-9#Aff2), * [Markus Schick](https://www.nature.com/articles/s41591-026-04716-9#auth-Markus-Schick-Aff3)[3](https://www.nature.com/articles/s41591-026-04716-9#Aff3), * [Ansh Kapil](https://www.nature.com/articles/s41591-026-04716-9#auth-Ansh-Kapil-Aff3)[3](https://www.nature.com/articles/s41591-026-04716-9#Aff3), * [Luis Paz-Ares](https://www.nature.com/articles/s41591-026-04716-9#auth-Luis-Paz_Ares-Aff4) [ORCID: orcid.org/0000-0002-1947-3364](https://orcid.org/0000-0002-1947-3364)[4](https://www.nature.com/articles/s41591-026-04716-9#Aff4), * [Aaron Lisberg](https://www.nature.com/articles/s41591-026-04716-9#auth-Aaron-Lisberg-Aff5)[5](https://www.nature.com/articles/s41591-026-04716-9#Aff5), * [Melissa L. Johnson](https://www.nature.com/articles/s41591-026-04716-9#auth-Melissa_L_-Johnson-Aff6) [ORCID: orcid.org/0000-0001-9874-1314](https://orcid.org/0000-0001-9874-1314)[6](https://www.nature.com/articles/s41591-026-04716-9#Aff6), * [Maurice Pérol](https://www.nature.com/articles/s41591-026-04716-9#auth-Maurice-P_rol-Aff7) [ORCID: orcid.org/0000-0002-3296-423X](https://orcid.org/0000-0002-3296-423X)[7](https://www.nature.com/articles/s41591-026-04716-9#Aff7), * [Toshio Shimizu](https://www.nature.com/articles/s41591-026-04716-9#auth-Toshio-Shimizu-Aff8)[8](https://www.nature.com/articles/s41591-026-04716-9#Aff8), * [Rebecca Heist](https://www.nature.com/articles/s41591-026-04716-9#auth-Rebecca-Heist-Aff9)[9](https://www.nature.com/articles/s41591-026-04716-9#Aff9), * [Alexander Spira](https://www.nature.com/articles/s41591-026-04716-9#auth-Alexander-Spira-Aff10)[10](https://www.nature.com/articles/s41591-026-04716-9#Aff10), * [Isamu Okamoto](https://www.nature.com/articles/s41591-026-04716-9#auth-Isamu-Okamoto-Aff11)[11](https://www.nature.com/articles/s41591-026-04716-9#Aff11), * [Nicolas Girard](https://www.nature.com/articles/s41591-026-04716-9#auth-Nicolas-Girard-Aff12)[12](https://www.nature.com/articles/s41591-026-04716-9#Aff12), * [Robin Cornelissen](https://www.nature.com/articles/s41591-026-04716-9#auth-Robin-Cornelissen-Aff13)[13](https://www.nature.com/articles/s41591-026-04716-9#Aff13), * [Elvire Pons-Tostivint](https://www.nature.com/articles/s41591-026-04716-9#auth-Elvire-Pons_Tostivint-Aff14)[14](https://www.nature.com/articles/s41591-026-04716-9#Aff14), * [Min Hee Hong](https://www.nature.com/articles/s41591-026-04716-9#auth-Min_Hee-Hong-Aff15) [ORCID: orcid.org/0000-0003-3490-2195](https://orcid.org/0000-0003-3490-2195)[15](https://www.nature.com/articles/s41591-026-04716-9#Aff15), * [Ricardo Zwirtes](https://www.nature.com/articles/s41591-026-04716-9#auth-Ricardo-Zwirtes-Aff16-Aff23)[16](https://www.nature.com/articles/s41591-026-04716-9#Aff16) [nAff23](https://www.nature.com/articles/s41591-026-04716-9#nAff23), * [Rachel Chiaverelli](https://www.nature.com/articles/s41591-026-04716-9#auth-Rachel-Chiaverelli-Aff17-Aff24) [ORCID: orcid.org/0009-0002-3950-9843](https://orcid.org/0009-0002-3950-9843)[17](https://www.nature.com/articles/s41591-026-04716-9#Aff17) [nAff24](https://www.nature.com/articles/s41591-026-04716-9#nAff24), * [Marlon Rebelatto](https://www.nature.com/articles/s41591-026-04716-9#auth-Marlon-Rebelatto-Aff18)[18](https://www.nature.com/articles/s41591-026-04716-9#Aff18), * [Matthew Sung](https://www.nature.com/articles/s41591-026-04716-9#auth-Matthew-Sung-Aff19) [ORCID: orcid.org/0009-0003-8443-039X](https://orcid.org/0009-0003-8443-039X)[19](https://www.nature.com/articles/s41591-026-04716-9#Aff19), * [Chuyu Deng](https://www.nature.com/articles/s41591-026-04716-9#auth-Chuyu-Deng-Aff20)[20](https://www.nature.com/articles/s41591-026-04716-9#Aff20), * [James Harper](https://www.nature.com/articles/s41591-026-04716-9#auth-James-Harper-Aff21)[21](https://www.nature.com/articles/s41591-026-04716-9#Aff21), * [Danielle Carroll](https://www.nature.com/articles/s41591-026-04716-9#auth-Danielle-Carroll-Aff21-Aff25)[21](https://www.nature.com/articles/s41591-026-04716-9#Aff21) [nAff25](https://www.nature.com/articles/s41591-026-04716-9#nAff25), * [Hadassah Sade](https://www.nature.com/articles/s41591-026-04716-9#auth-Hadassah-Sade-Aff3) [ORCID: orcid.org/0009-0001-0634-2584](https://orcid.org/0009-0001-0634-2584)[3](https://www.nature.com/articles/s41591-026-04716-9#Aff3) & * … * [Jacob Sands](https://www.nature.com/articles/s41591-026-04716-9#auth-Jacob-Sands-Aff22)[22](https://www.nature.com/articles/s41591-026-04716-9#Aff22) Show authors [_Nature Medicine_](https://www.nature.com/nm) (2026) [Cite this article](https://www.nature.com/articles/s41591-026-04716-9#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) ## Abstract Datopotamab deruxtecan (Dato-DXd)—a trophoblast cell surface antigen 2 (TROP2)-directed antibody–drug conjugate—has demonstrated efficacy in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) ± actionable genomic alterations. However, TROP2 expression by pathologist assessment using conventional immunohistochemistry with visual scoring does not predict response to TROP2-directed antibody–drug conjugates in NSCLC. We developed TROP2 quantitative continuous scoring (QCS)—a fully supervised computational pathology approach that quantifies TROP2 expression in individual NSCLC cells and subcellular components from immunohistochemistry-stained slides. Using QCS to determine TROP2 expression at the tumor cell membrane and cytoplasm, normalized membrane ratio (NMR) was developed (ratio of membrane relative to membrane + cytoplasmic TROP2) in the biomarker-evaluable population of patients with advanced NSCLC in the TROPION-PanTumor01 study (_n_ = 115). The TROP2 NMR cut-point was optimized and validated in patients with nonsquamous NSCLC without actionable genomic alterations (primary intended-use population, _n_ = 221) in the biomarker-evaluable population (_n_ = 352) of the TROPION-Lung01 trial. Association with clinical outcomes was assessed. Progression-free survival was longer in Dato-DXd-treated (median 7.2 versus 4.0 months; hazard ratio 0.40, 95% confidence interval 0.25–0.64) but not docetaxel-treated (median 4.1 versus 4.4 months; hazard ratio 0.94, 95% confidence interval 0.59–1.49) patients with TROP2 NMR-positive versus TROP2 NMR-negative samples (treatment by biomarker status interaction _P_ = 0.0098), indicating that TROP2 NMR may be a predictive biomarker for Dato-DXd. ### Explore related subjects Discover the latest articles and news in related subjects. * [Cancer imaging](https://www.nature.com/subjects/cancer-imaging) * [Non-small-cell lung cancer](https://www.nature.com/subjects/non-small-cell-lung-cancer) * [Targeted Therapies in HER2-Positive Breast Cancer](https://www.nature.com/subjects/targeted-therapies-in-her2-positive-breast-cancer) ## Main Lung cancer is the leading cause of cancer-related mortality worldwide, with an estimated 1.8 million deaths globally in 2020[1](https://www.nature.com/articles/s41591-026-04716-9#ref-CR1 "World Health Organization. GLOBOCAN https://gco.iarc.fr/today/en \(2025\)."). Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and, despite advances in early detection, more than half of patients are diagnosed with advanced or metastatic disease, which has a 5-year survival rate of approximately 10%[2](https://www.nature.com/articles/s41591-026-04716-9#ref-CR2 "Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F. & Heist, R. S. Lung cancer. Lancet 398, 535–554 \(2021\)."),[3](https://www.nature.com/articles/s41591-026-04716-9#ref-CR3 "Zhang, Y. et al. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 24, 1206–1218 \(2023\)."),[4](https://www.nature.com/articles/s41591-026-04716-9#ref-CR4 "National Cancer Institute Surveillance Research Program. SEER*Explorer. An interactive website for SEER cancer statistics https://seer.cancer.gov/statistics-network/explorer/ \(2025\)."). Advances in precision medicine, such as anaplastic lymphoma kinase (ALK)- and epidermal growth factor receptor (EGFR)-targeted therapies, have dramatically improved outcomes for patients with resectable, locally advanced and metastatic NSCLC with actionable genomic alterations (AGAs)[5](https://www.nature.com/articles/s41591-026-04716-9#ref-CR5 "Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113–125 \(2018\)."),[6](https://www.nature.com/articles/s41591-026-04716-9#ref-CR6 "Wu, Y. L. et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 383, 1711–1723 \(2020\)."),[7](https://www.nature.com/articles/s41591-026-04716-9#ref-CR7 "Lu, S. et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N. Engl. J. Med. 391, 585–597 \(2024\)."). Immune checkpoint inhibitors have significantly improved treatment outcomes for patients with early-stage and advanced or metastatic NSCLC lacking AGAs[8](https://www.nature.com/articles/s41591-026-04716-9#ref-CR8 "Phillips, W. J. et al. Immunotherapy for early-stage non-small cell lung cancer: a practical guide of current controversies. Clin. Lung Cancer 26, 179–190 \(2025\)."),[9](https://www.nature.com/articles/s41591-026-04716-9#ref-CR9 "Hendriks, L. E. et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 358–376 \(2023\)."), and immunotherapy, alone or with chemotherapy, is the recommended first-line (1L) standard-of-care treatment[9](https://www.nature.com/articles/s41591-026-04716-9#ref-CR9 "Hendriks, L. E. et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 358–376 \(2023\)."). However, only 20–40% of patients achieve a response, and fewer experience long-term disease remission[10](https://www.nature.com/articles/s41591-026-04716-9#ref-CR10 "Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345–362 \(2021\)."), with later lines of therapy offering limited clinical benefit[9](https://www.nature.com/articles/s41591-026-04716-9#ref-CR9 "Hendriks, L. E. et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 358–376 \(2023\)."),[10](https://www.nature.com/articles/s41591-026-04716-9#ref-CR10 "Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345–362 \(2021\)."),[11](https://www.nature.com/articles/s41591-026-04716-9#ref-CR11 "Goldschmidt, J. H. et al. Treatment patterns and clinical outcomes among patients with metastatic non-small cell lung cancer without actionable genomic alterations previously treated with platinum-based chemotherapy and immunotherapy. Drugs Real World Outcomes 11, 425–439 \(2024\)."). Antibody–drug conjugates (ADCs) comprise a cytotoxic payload linked to an antibody directed towards a tumor-associated antigen. This allows targeted payload delivery with the aim of enhancing efficacy and reducing off-target toxicity[12](https://www.nature.com/articles/s41591-026-04716-9#ref-CR12 "Parslow, A. C., Parakh, S., Lee, F. T., Gan, H. K. & Scott, A. M. Antibody-drug conjugates for cancer therapy. Biomedicines 4, 14 \(2016\)."),[13](https://www.nature.com/articles/s41591-026-04716-9#ref-CR13 "Chau, C. H., Steeg, P. S. & Figg, W. D. Antibody-drug conjugates for cancer. Lancet 394, 793–804 \(2019\)."),[14](https://www.nature.com/articles/s41591-026-04716-9#ref-CR14 "Nakada, T., Sugihara, K., Jikoh, T., Abe, Y. & Agatsuma, T. The latest research and development into the antibody-drug conjugate, \[fam-\] trastuzumab deruxtecan \(DS-8201a\), for HER2 cancer therapy. Chem. Pharm. Bull. \(Tokyo\) 67, 173–185 \(2019\)."). TROP2—a transmembrane glycoprotein—is expressed in various solid tumors, and approximately 90% of tumor samples from patients with NSCLC express TROP2 (refs. [15](https://www.nature.com/articles/s41591-026-04716-9#ref-CR15 "Guo, X. et al. Tumor-associated calcium signal transducer 2 regulates neovascularization of non-small-cell lung cancer via activating ERK1/2 signaling pathway. Tumour Biol. 39, 1010428317694324 \(2017\)."),[16](https://www.nature.com/articles/s41591-026-04716-9#ref-CR16 "Jiang, A., Gao, X., Zhang, D., Zhang, L. & Lu, H. Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma. Oncol. Lett. 6, 375–380 \(2013\)."),[17](https://www.nature.com/articles/s41591-026-04716-9#ref-CR17 "Li, Z., Jiang, X. & Zhang, W. TROP2 overexpression promotes proliferation and invasion of lung adenocarcinoma cells. Biochem. Biophys. Res. Commun. 470, 197–204 \(2016\)."),[18](https://www.nature.com/articles/s41591-026-04716-9#ref-CR18 "Heist, R. S. et al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan. J. Clin. Oncol. 35, 2790–2797 \(2017\)."),[19](https://www.nature.com/articles/s41591-026-04716-9#ref-CR19 "Omori, S. et al. Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments. J. Cancer Res. Clin. Oncol. 148, 2455–2463 \(2022\)."),[20](https://www.nature.com/articles/s41591-026-04716-9#ref-CR20 "Inamura, K. et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget 8, 28725–28735 \(2017\)."),[21](https://www.nature.com/articles/s41591-026-04716-9#ref-CR21 "Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A. & Sharkey, R. M. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan \(IMMU-132\), an antibody-drug conjugate \(ADC\). Oncotarget 6, 22496–22512 \(2015\)."),[22](https://www.nature.com/articles/s41591-026-04716-9#ref-CR22 "Goldenberg, D. M., Stein, R. & Sharkey, R. M. The emergence of trophoblast cell-surface antigen 2 \(TROP-2\) as a novel cancer target. Oncotarget 9, 28989–29006 \(2018\).
## Related Clinical Research

- [Next-generation antibody therapeutics in cancer: ADCs and bispecific antibodies in hematologic and](https://medichelpline.com/clinical-feed/pubmed-42711696.md) (DOI: 10.1186/s13045-026-01843-1)
- [53L10 T‑cell engager tribody for immunotherapy of multiple solid tumors — Frontiers in Immunology](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-53l10-t-cell-engager-tribody-for-immunotherapy-of-multiple-solid-tumors.md)
- [Increased 1-Year Risk of Ischemic Stroke After Invasive Cancer Diagnosis: Nationwide Cohort Study](https://medichelpline.com/clinical-feed/pubmed-42706874.md) (DOI: 10.1002/cncr.70536)
- [HER2-targeted antibody–molecular glue conjugate drives selective cyclin K degradation](https://medichelpline.com/clinical-feed/biorxiv-10-a-molecular-glue-degrader-antibody-conjugate-for-her2-targeted-cyclin-k.md)
- [5-year iDFS After PET-Guided Chemotherapy De-escalation in HER2-Positive Early Breast Cancer (PHER](https://medichelpline.com/clinical-feed/nature-0-5-year-outcomes-of-chemotherapy-de-escalation-in-her2-positive-early-breast.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.